{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["M-CENK","nogapendekin alfa inbakicept (N-803)"]],"indication":"locally advanced or metastatic solid tumors","name":"QUILT-3.076","nct_id":"NCT04898543","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=quilt-3-076-nct04898543. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Cohort 1: Subjects with either newly diagnosed solid tumors who have not received prior therapy or subjects who have received prior first line treatment. Cohort 1 may subsequently enroll in cohort 2 part B if they have progressive disease after ≥ 2 prior therapies or if they have progressive disease within 12 months of receiving neoadjuvant or adjuvant chemotherapy and meet the inclusion criteria for cohort 2 part B.","label":"Cohort 1: Subjects newly diagnosed no prior therapy or prior first line treatment","type":"EXPERIMENTAL"},{"description":"Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies or not a candidate for therapy of proven efficacy for their disease.","label":"Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-05-31","type":"ESTIMATED"},"conditions":["Metastatic Solid Tumor"],"enrollment":{"count":50,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)","otherNames":[],"type":"BIOLOGICAL"},{"name":"N-803 (Cohort 2 part B)","otherNames":[],"type":"BIOLOGICAL"},{"name":"Apheresis collection of MNCs (part A)","otherNames":[],"type":"OTHER"}],"last_update":"2026-11-02","lead_sponsor":"ImmunityBio, Inc.","official_title":"Phase 1 Open-Label Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-02-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to apheresis.","timeFrame":"Study Day 1, assessed for up to 1 week"},{"measure":"Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of participants with clinically significant laboratory tests.","timeFrame":"From Baseline/Screening through Study Day 1, assessed for up to 1 day"},{"measure":"Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by number of participants with abnormal vital signs.","timeFrame":"From Baseline/Screening through Study Day 1, assessed for up to 28 days"},{"measure":"Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of TEAEs and SAEs after the first dose of M-CENK and the first dose of N-803 (M-CENK Dose Number 1)","timeFrame":"From M-CENK Dose Number 1 up to 30 days, assessed for up to 30 days"},{"measure":"Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with clinically significant laboratory tests","timeFrame":"From M-CENK Dose Number 1, assessed for up to 1 day"},{"measure":"Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with abnormal vital signs","timeFrame":"From M-CENK Dose Number 1, assessed for up to 1 day"}],"references":[],"start_date":{"date":"2021-06-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors","url":"https://clinicaltrials.gov/study/NCT04898543"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/quilt-3-076-nct04898543"}